MedTrace Logo

Zonisamide for Fibromyalgia & Migraine

NCT00259636 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-06-01

No results posted yet for this study

Summary

Patients with fibromyalgia \& migraine are randomized to receive zonisamide or placebo.

Conditions

Interventions

DRUG

zonisamide

zonisamide 100 mg -300 mg daily vs placebo

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Dawn Marcus, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259636 on ClinicalTrials.gov